Literature DB >> 1988755

Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin.

J A Etchason1, T D Miller, R W Squires, T G Allison, G T Gau, J K Marttila, B A Kottke.   

Abstract

Hepatitis developed in five patients who were taking low dosages (3 g/day or less) of time-release niacin. In four of the five patients, clinical symptoms of hepatitis developed after the medication had been taken for a relatively short time (2 days to 7 weeks). This manifestation of hepatotoxicity seems to differ from that previously reported in association with use of crystalline niacin, which occurred with high dosage and prolonged usage of the medication. In view of the recent increased frequency of prescribing niacin for the treatment of hyperlipidemia, physicians should be aware of the potential for hepatotoxicity with even low-dose and short-term use of time-release niacin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1988755     DOI: 10.1016/s0025-6196(12)61171-9

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  14 in total

1.  Niacin--the long and the short of it.

Authors:  M J Malloy; P H Frost; J P Kane
Journal:  West J Med       Date:  1991-10

Review 2.  Niacin: another look at an underutilized lipid-lowering medication.

Authors:  Julia C Creider; Robert A Hegele; Tisha R Joy
Journal:  Nat Rev Endocrinol       Date:  2012-02-21       Impact factor: 43.330

Review 3.  How well tolerated are lipid-lowering drugs?

Authors:  B Tomlinson; P Chan; W Lan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Discovery of a potent nicotinic Acid receptor agonist for the treatment of dyslipidemia.

Authors:  Jun Qin; Ashwin Rao; Xiao Chen; Xiaohong Zhu; Zhidan Liu; Xianhai Huang; Sylvia Degrado; Ying Huang; Dong Xiao; Robert Aslanian; Boonlert Cheewatrakoolpong; Hongtao Zhang; Scott Greenfeder; Constance Farley; John Cook; Stan Kurowski; Qiu Li; Margaret van Heek; Madhu Chintala; Ganfeng Wang; Yunsheng Hsieh; Fangbiao Li; Anandan Palani
Journal:  ACS Med Chem Lett       Date:  2010-12-08       Impact factor: 4.345

5.  Clinical associations of hepatic stellate cell (HSC) hyperplasia.

Authors:  Taofic Mounajjed; Rondell P Graham; Schuyler O Sanderson; Thomas C Smyrk
Journal:  Virchows Arch       Date:  2014-05-09       Impact factor: 4.064

Review 6.  Nicotinic acid: an old drug with a promising future.

Authors:  E T Bodor; S Offermanns
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

Review 7.  Lipid-lowering agents that cause drug-induced hepatotoxicity.

Authors:  Sidharth S Bhardwaj; Naga Chalasani
Journal:  Clin Liver Dis       Date:  2007-08       Impact factor: 6.126

Review 8.  Evaluation and management of dyslipidemia in patients with HIV infection.

Authors:  Michael L Green
Journal:  J Gen Intern Med       Date:  2002-10       Impact factor: 5.128

Review 9.  Niacin, an old drug with a new twist.

Authors:  Wen-Liang Song; Garret A FitzGerald
Journal:  J Lipid Res       Date:  2013-08-15       Impact factor: 5.922

Review 10.  Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.

Authors:  Fatima Iqbal; Wendy S Baker; Madiha I Khan; Shwetha Thukuntla; Kevin H McKinney; Nicola Abate; Demidmaa Tuvdendorj
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.